The company founded by Moritz Plieger, Raphael Tazreiter and Hanspeter Rottensteiner is focused on addressing underlying disease mechanisms in severe metabolic and neuroendocrine disorders, an area where treatment options remain limited and significant unmet medical needs persist.
Founded by an alumnus of the xbio biomedical incubation programme, led by XISTA and the University of Vienna, Aperio is pursuing a differentiated approach built around a biological pathway that is increasingly attracting attention from clinicians, researchers, and the broader life sciences community. By targeting a mechanism that is implicated across multiple related conditions, the company aims to create a platform with the potential to generate impact beyond a single indication while addressing significant unmet patient needs.
Aperio stands out through a multidisciplinary team that brings together clinical insight, biochemistry expertise, and pharmaceutical development experience. By applying this combination of scientific and operational capabilities to an underexplored area of human biology, the company aims to unlock new therapeutic opportunities across metabolic disorders.
Why we invested
Aperio Therapeutics combines a compelling scientific rationale with a clearly defined development strategy and a team that brings together medical, scientific, and entrepreneurial expertise. The company is addressing a major unmet need while pursuing an approach that could have relevance across multiple related diseases, creating the potential for both meaningful patient impact and long-term value creation.
XISTA Team
